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CONTEMPORARY REVIEW
Clinical Potential of Targeting Fibroblast 
Growth Factor- 23 and αKlotho in the 
Treatment of Uremic Cardiomyopathy
Jonathan P. Law, MBChB; Anna M. Price, MBChB; Luke Pickup, MBChB; Ashwin Radhakrishnan, BM;  
Chris Weston, BSc, PhD; Alan M. Jones, BSc, PhD; Helen M. McGettrick, BSc, MSc, PhD; Winnie Chua, BA, PhD; 
Richard P. Steeds, MD; Larissa Fabritz, MD; Paulus Kirchhof, MD; Davor Pavlovic, BSc, DPhil*;  
Jonathan N. Townend, MD*; Charles J. Ferro , MD*
ABSTRACT: Chronic kidney disease is highly prevalent, affecting 10% to 15% of the adult population worldwide and is asso-
ciated with increased cardiovascular morbidity and mortality. As chronic kidney disease worsens, a unique cardiovascular 
phenotype develops characterized by heart muscle disease, increased arterial stiffness, atherosclerosis, and hypertension. 
Cardiovascular risk is multifaceted, but most cardiovascular deaths in patients with advanced chronic kidney disease are 
caused by heart failure and sudden cardiac death. While the exact drivers of these deaths are unknown, they are believed 
to be caused by uremic cardiomyopathy: a specific pattern of myocardial hypertrophy, fibrosis, with both diastolic and sys-
tolic dysfunction. Although the pathogenesis of uremic cardiomyopathy is likely to be multifactorial, accumulating evidence 
suggests increased production of fibroblast growth factor- 23 and αKlotho deficiency as potential major drivers of cardiac 
remodeling in patients with uremic cardiomyopathy. In this article we review the increasing understanding of the physiology 
and clinical aspects of uremic cardiomyopathy and the rapidly increasing knowledge of the biology of both fibroblast growth 
factor- 23 and αKlotho. Finally, we discuss how dissection of these pathological processes is aiding the development of thera-
peutic options, including small molecules and antibodies, directly aimed at improving the cardiovascular outcomes of patients 
with chronic kidney disease and end- stage renal disease.
Key Words: αKlotho ■ cardiorenal syndrome ■ FGF23 ■ fibroblast growth factor ■ growth factor ■ kidney ■ treatment
Chronic kidney disease (CKD) and end- stage renal disease (ESRD) requiring dialysis are complex, chronic conditions with a combined prevalence 
of 10% to 15% of the adult population worldwide.1–3 
Cardiovascular events and mortality increase expo-
nentially with reduced estimated glomerular filtra-
tion rate (eGFR) independent of age, sex, and other 
risk factors.4–6 In the early stages of CKD, the risks 
of occlusive atheromatous disease are increased 
and account for the majority of cardiovascular events 
observed.7 Arterial atheroma remains an important 
modifiable pathophysiological process in CKD, as 
evidenced by trials in early CKD showing benefit from 
lipid- lowering therapies in modifying the risk of ath-
erosclerotic events.8–10 However, the same treatments 
appear much less effective in patients with advanced 
stages of CKD, including ESRD.10–12 As CKD wors-
ens, there is a shift from atherosclerotic complications 
to morbidity due to heart failure and sudden cardiac 
death (SCD).7,13,14 Atrial fibrillation (AF) is also common, 
detected in up to 41% of patients requiring hemodial-
ysis.14 The pathophysiological basis of these events is 
a unique cardiovascular phenotype consisting primar-
ily of the development of uremic cardiomyopathy with 
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associated increased arterial stiffness and widespread 
atheroma.
The purpose of this article is to review the current 
state of the art on 2 newly postulated drivers of uremic 
cardiomyopathy, elevated circulating fibroblast growth 
factor- 23 (FGF23) and reduced αKlotho, and discuss 
how recent insights into the pathophysiological pro-
cesses has led to development of potential therapeutic 
options aimed at reducing the cardiovascular risk of 
patients with CKD/ESRD.
UREMIC CARDIOMYOPATHY
The term uremic cardiomyopathy arose in the 1980s 
with reports of common abnormalities in cardiac 
function and structure in patients with CKD/ESRD, 
including increased left ventricular (LV) mass and left 
ventricular hypertrophy (LVH); diastolic and systolic 
dysfunction; as well as profound myocardial fibrosis on 
histology.15–20 Uremic cardiomyopathy has been linked 
to conditions causing both heart failure and CKD, es-
pecially hypertension. Chronic stimulation of cardiac 
cells by renin, angiotensin, parathyroid hormone (PTH), 
cardiotonic steroids, and other uremic toxins, has also 
been proposed.20 The severity of uremic cardiomyo-
pathy as measured by LV mass is a powerful predictor 
of cardiovascular mortality probably as a result of the 
factors discussed below.
Increased LV Mass and Hypertrophy
Increased LV mass and LVH are common manifesta-
tions of uremic cardiomyopathy. Forty percent of pa-
tients with an eGFR <30  mL/min per 1.73  m2 have 
LVH on echocardiography,21 increasing to ≈80% in 
ESRD.22,23 In patients with CKD/ESRD, LVH is strongly 
associated with death; diastolic and systolic heart fail-
ure; and cardiac arrhythmias.22,23 However, LV mass is 
a continuous variable, with a graded relationship with 
adverse cardiovascular outcomes.24–28 It is also im-
portant to emphasize that cardiac structural changes 
occur early in the course of CKD, with a linear asso-
ciation between worsening renal function and a higher 
prevalence of LVH.29,30 While elevated blood pressure 
is an important determinant of LV mass,31 evidence 
from both animal and human studies supports the 
presence of mechanisms that are independent of 
pressure overload and hypertension in driving cardiac 
hypertrophy in CKD/ESRD.32–36
Diastolic and Systolic Dysfunction
Diastolic dysfunction is highly prevalent in patients 
with CKD, with over two thirds affected in CKD stages 
2 to 430 and up to 85% in ESRD.37 Diastolic dysfunc-
tion is strongly associated with increased LV mass 
and LVH,7 as well as myocardial fibrosis,20,38 and 
correlates with increased mortality.37,38 Furthermore, 
the presence of diastolic dysfunction is considered 
to be a major cause for the frequent presentation of 
hemodialysis patients with pulmonary edema or in-
tradialytic hypotension, despite only minor changes 
in fluid status.7,38
Overt LV systolic dysfunction, as manifested by re-
duced ejection fraction, is uncommon in predialysis 
CKD with a reported prevalence of 8% and no asso-
ciation with eGFR.17,30 However, several studies using 
echocardiography have shown changes in LV defor-
mation in early stages of CKD, indicating the presence 
of subnormal LV systolic function.39–41 In ESRD, LV 
systolic dysfunction is very common, with a reported 
prevalence 10 to 30 times greater than in the general 
population.42,43
Myocardial Fibrosis
It has been suggested that increased interstitial myo-
cardial fibrosis may be the unifying pathophysiologi-
cal process underlying uremic cardiomyopathy.44 In 
the 1990s, a postmortem study found that myocardial 
fibrosis was present in 91% of CKD/ESRD patients 
without significant flow- limiting coronary lesions. The 
severity of fibrosis was related to the length of time on 
dialysis, but independent of hypertension, blood pres-
sure, diabetes mellitus, or anemia.15 Over a decade 
later, Aoki et al.16 performed endocardial biopsies in 40 
ESRD patients with reduced LV ejection fraction with-
out coronary artery disease. The predominant path-
ologic findings were extensive interstitial fibrosis and 
cardiomyocyte hypertrophy and disarray.
Studying myocardial fibrosis in CKD/ESRD has been 
challenging given that myocardial biopsies are not with-
out risk, especially in multimorbid patients and therefore 
are not always clinically and ethically justified.45,46 Late 
gadolinium enhancement cardiac magnetic resonance 
imaging, a validated noninvasive method, allows in vivo 
quantification of myocardial fibrosis in conditions such 
as myocardial infarction,47 dilated48 and hypertrophic 
cardiomyopathies.49 This technique has also been used 
to characterize myocardial tissue in patients with ESRD 
demonstrating midwall patterns of late gadolinium en-
hancement consistent with replacement myocardial 
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
ESRD end-stage renal disease
FGF23 fibroblast growth factor 23
LV left ventricular
LVH left ventricular hypertrophy
SCD sudden cardiac death
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fibrosis not associated with large vessel coronary artery 
disease.17 Noncontrast myocardial native T1 relaxation 
time, or T1 mapping, has emerged as a novel viable 
technique to quantify diffuse interstitial myocardial fi-
brosis in CKD/ESRD50 correlating with histological inter-
stitial fibrosis in a number of disease states, including 
cardiomyopathy and valvular disease.51 Indeed, native 
T1 times are increased in early CKD,19 increasing with 
worsening CKD stages52 and correlates with increased 
LV mass.18,53 Native T1 mapping offers an exciting op-
portunity to investigate novel mechanisms of cardiac 
fibrosis (eg, FGF23- mediated changes), in patients with 
CKD and in animal models.
FIBROBLAST GROWTH FACTOR- 23 
AND αKLOTHO
The hormone FGF23, first discovered in 2000, is a 
circulating growth factor secreted by osteocytes 
whose main physiological role is to increase urinary 
phosphate excretion.54,55 The 4 mammalian FGF re-
ceptors (FGFR1- 4) are membrane- bound receptor 
tyrosine kinases.56,57 FGFR1 is suggested to be the 
primary FGF23 receptor in target organs—the kidneys 
and parathyroid glands.58–61 Crystallography studies 
clearly demonstrate that the presence of αKlotho is 
required for the efficient binding of FGF23 to FGFR1.62 
αKlotho is a cell- surface protein, mainly expressed in 
the kidneys and parathyroid glands.63–65 In addition to 
the membrane- associated full- length protein, the ec-
todomain of αKlotho can exist in a soluble form.66–69 
In the presence of membrane- bound αKlotho or sol-
uble αKlotho, FGF23 can activate Fibroblast Growth 
Factor Receptor Substrate- 2 (FRS2α)/Ras/Mitogen- 
Activated Protein Kinase signaling (Figure  1).62,70,71 
Soluble αKlotho, therefore, may act as a circulat-
ing FGF23 coreceptor in cells that do not express 
αKlotho. Such a mechanism has been reported in 
osteoblasts.72 However, its role in the heart is yet to 
be fully characterized as neither cardiomyocytes nor 
cardiac fibroblasts express αKlotho.55 It is possible 
that FGF23 might act on these cells with circulating 
αKlotho as a cofactor. Treatment of cardiac myofi-
broblasts with full- length αKlotho resulted in upregu-
lated proliferation and ERK phosphorylation, which 
was suppressed by FGFR1 antagonism.73 This sug-
gests the presence of FGFR1 in cardiac myofibro-
blasts for which soluble Klotho acts as a circulating 
co- receptor, although the authors did not comment 
on endogenous FGFR1/FGF23 expression.
FGF23 can also exert cellular effects via αKlotho- 
independent mechanisms.74 FGF23 has been shown 
to stimulate phospholipase Cγ (PLCγ)/calcineurin/nu-
clear factor of activated T- cells (NFAT) via FGFR4 in 
cells that lack αKlotho (Figure 1).74–77 Such increases 
in PLCγ/calcineurin/NFAT signaling appear to be im-
portant in pathological, as opposed to physiological, 
cardiac hypertrophy.78,79 Clearly further mechanistic 
studies are warranted to delineate mechanisms that 
can be targeted therapeutically in patients with ele-
vated FGF23 levels.
FGF23, αKLOTHO, AND KIDNEY 
DISEASE
One of the first clinically detectable signs of CKD is 
an elevation in serum FGF23, probably in response to 
increased extracellular phosphate, although the de-
tails of the stimulus and its detection are still unclear, 
with levels rising steeply as kidney function wors-
ens54,80 (Figure  2). Indeed, elevations are observed 
as early as eGFR 75 mL/min per 1.73 m2, long be-
fore increased concentrations in PTH or phosphate 
are observed.80 Circulating FGF23 levels are 2- to 
5- fold above the normal range in early/intermediate 
CKD, but can reach levels of 1000- fold above nor-
mal in ESRD.80–82 Increased FGF23 levels are also 
found in heart failure83–88 and AF,89–93 and are as-
sociated with all- cause and cardiovascular mortality 
in patients with and without CKD.87,88,94–99 Ongoing 
research therefore explores FGF23 as both a poten-
tial biomarker100 and a causative factor for cardiac 
mechanoelectrical dysfunction. However, effective 
quantification of circulating FGF23 is not currently 
standardized. Several FGF23 assay kits utilize differ-
ing detection techniques, epitope binding regions, 
analytical ranges and measurement units, making 
direct comparisons challenging.101
The kidney is the principal source of circulating 
soluble αKlotho.69,102 Its levels are downregulated in 
the presence of albuminuria,103 inflammation,104 and 
with the progression of CKD. αKlotho levels start to 
decline in CKD stage 2 and precede the elevation of 
FGF23, PTH, and serum phosphate.105 Low levels of 
circulating αKlotho are associated with increased car-
diovascular events and mortality in patients with CKD/
ESRD.106–109 It is, therefore, conceivable that some of 
the adverse physiological effects that have been at-
tributed to increased FGF23 may be either caused by, 
or compounded by, lower αKlotho (Figure  2). These 
mechanistic complexities require further investigation 
and need to be considered when developing FGF23/
αKlotho- directed therapies.
FGF23, αKLOTHO, AND LEFT 
VENTRICULAR MASS/HYPERTROPHY
The heart has been shown to respond to FGF23, in-
creasing LV mass independently of blood pressure, 
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promoting cardiac fibrosis and reducing LV systolic 
function in animal models.74,75,77,110,111 Elevations of 
cardiac FGFR4 and enhanced PLCγ/calcineurin/NFAT 
signaling have been observed in both animal mod-
els of CKD and in patients with CKD/ESRD.75,112–114 
Several studies have shown that repetitive adminis-
tration of FGF23 in wild- type mice, either intravenous 
or intraperitoneal, induced cardiac hypertrophy within 
5 days.74,110,111 The signaling actions of FGF23 on the 
heart are still not fully characterized. However, several 
independent experimental approaches demonstrate 
the involvement of the αKlotho- independent FGFR4- 
PLCγ/calcineurin/NFAT signaling pathway in cardiomy-
ocytes.74,75,77 On the other hand, independent studies 
demonstrate that αKlotho may be cardioprotective and 
that subnormal levels may be required for FGF23 to in-
duce LVH.115–118 Although many of the studies indicate 
that elevation of FGF23 and reduction in αKlotho are 
involved in the development of LVH, recent studies by 
Leifheit- Nestler and Slavic have not recapitulated these 
findings.119,120 Chronic FGF23 overexpression (via myo-
cardial gene transfer), or genetic ablation of FGF23 or 
αKlotho on the background of transverse aortic constric-
tion did not affect cardiac function or morphology.119,120
FIBROBLAST GROWTH FACTOR- 23, 
αKLOTHO, AND MYOCARDIAL 
FIBROSIS
Every third to fourth cell in the heart is a fibroblast. 
Fibroblasts produce the extracellular matrix in the 
heart and act as regulators of the cardiac interstit-
ium.121,122 In the injured myocardium, inflammation and 
Figure 1. Potential mechanisms of fibroblast growth factor- 23 (FGF23) signal transduction and signaling pathways.
Fibroblast growth factor- 23 (FGF23) acts on cells that constitutively express fibroblast growth factor receptor- 1 (FGFR1) and its 
coreceptor αKlotho. In cells that do not constitutively express αKlotho, such as cardiac myocytes and fibroblasts, circulating αKlotho 
is thought to perform a role similar to membrane- bound αKlotho. Circulating FGF23 can also bind to other FGFR1 and other FGFR 
independently of αKlotho. In cardiac myocytes, this is thought to be FGFR4 predominantly. The binding of FGF23 to an FGFR1- αKlotho 
complex activates MAPK (mitogen-activated protein kinase), upregulating early growth response protein- 1 (EGR1), thereby modulating 
physiological gene expression. In the absence of αKlotho, FGF23 binding to either FGFR1 or FGFR4 activates phospholipase Cγ1 
(PLCγ1), increasing intracellular calcium. This in turn activates calcineurin to dephosphorylate (P, in red) nuclear factor of activated 
T- cells (NFAT), which induces pathophysiological gene transcription.
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mechanical stress promote activation of fibroblasts 
to myofibroblasts, leading to maladaptive deposition 
of extensively cross- linked extracellular matrix, which 
drives increased stiffness and impaired mechano-
electrical coupling of cardiomyocytes. This loss of 
cardiomyocyte coupling not only leads to attenuated 
cardiac function, but also provides a substrate for ar-
rhythmias.123–126 Although recent studies have shown 
that FGF23 can activate cardiac fibroblasts, neither 
the underlying mechanism127,128 nor its role in the de-
velopment of cardiac fibrosis are fully defined.127,129 As 
cardiac fibroblasts do not express αKlotho,74,102,113,114 
the alternative pathway of αKlotho- independent FGF23 
signaling through FGFR4- PLCγ/calcineurin/NFAT is 
likely to play a role (Figure  1). Future studies are re-
quired to examine which FGF receptors are expressed 
in cardiac fibroblasts, whether FGF23 contributes to 
cardiac fibrosis, and whether these mechanisms are 
dependent on αKlotho.
FGF 23, αKLOTHO, AND CARDIAC 
ARRHYTHMIAS
Patients with CKD/ESRD are at increased risk of a wide 
spectrum of cardiac arrhythmias, including supraven-
tricular tachycardias, particularly AF, and potentially 
lethal ventricular arrhythmias.14,130,131 All 3 compo-
nents of uremic cardiomyopathy (increased LV mass/
LVH; diastolic and systolic dysfunction; and especially 
myocardial fibrosis) are associated with arrhythmo-
genesis.131,132 While emerging evidence from implant-
able loop recorder studies is beginning to implicate 
bradyarrhythmias as the major cause of SCD in ESRD, 
rather than the previously assumed tachyarrhythmias, 
the precise causes of SCD in ESRD are the subject 
of investigation.14 αKlotho has been found in sinoatrial 
node pacemaker cells in mice133 and αKlotho- deficient 
animals exhibit sinoatrial node dysfunction, and higher 
rates of bradyarrhythmias and SCD.133
Figure 2. Dynamic interplay of fibroblast growth factor- 23–αKlotho axis.
Dietary phosphate (Pi) ingestion and absorption leads to osteocytes secreting fibroblast growth factor- 23 (FGF23). It is not clear 
how osteocytes detect circulating phosphate, but the sensing of calciprotein particles (nanoparticles consisting of calcium, 
phosphate, and fetuin A) has been proposed as a potential mechanism. Increased FGF23 leads to increased phosphate 
excretion by downregulating sodium- dependent phosphate cotransporter IIa/c, via mitogen- activated protein kinase signaling, 
in the renal proximal tubules expressing FGF- receptor 1 (FGFR1) in an αKlotho- dependent manner. In addition, FGF23 
lowers renal vitamin D hydroxylation and decreases parathyroid hormone (PTH) secretion, both actions also being αKlotho- 
dependent, reducing calcium entry into the circulation. In the context of reducing renal function, FGF23 production increases 
to compensate for reduced renal phosphate excretion, decreased activated vitamin D levels, and rising PTH secretion. High 
levels of circulating FGF23 have been implicated in the development of uremic cardiomyopathy through αKlotho- independent 
mechanisms via either the FGFR1 or, more likely, FGFR4. Circulating αKlotho may mitigate some of the pathophysiological 
actions of FGF23 on the myocardium. However, the kidneys are the main source of circulating αKlotho and levels decrease 
with reducing renal function.
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FGF23 distrupts intracellular calcium cycling within 
the cardiomyocyte, which is an important risk factor 
for arrhythmogenesis.134–136 Administration of FGF23 
to rat ventricular cardiomyocytes caused calmodulin- 
dependent protein kinase II- dependent aberrant in-
tracellular calcium, resulting in in vitro and in vivo 
arrhythmogenicity.137 Administration of recombinant 
αKlotho or a pan- FGFR blocker prevented contractile 
dysfunction and reduced pro- arrhythmogenic activity.137
Large observational studies in patients with CKD or AF 
and in the general population have found an association 
between elevated FGF23 and increased risk of develop-
ing AF.89,138 High FGF23 and low αKlotho levels are asso-
ciated with periods of AF in patients with paroxysmal or 
persistent AF.91 Increased expression of FGF23, FGFR4 
mRNA, and FGFR4 protein in the right atrial appendages 
of patients with AF has been reported and positively cor-
relate with atrial collagen fraction. Collectively these data/
studies suggest that FGF23/FGFR4 may play a role in 
promoting AF through atrial fibrosis.139
REVERSING OR PREVENTING UREMIC 
CARDIOMYOPATHY BY TARGETING 
THE FGF23 AND αKLOTHO AXIS
Several therapies exist that directly or indirectly target 
FGF23, αKlotho, and abnormalities in bone metabo-
lism. These are reviewed below and summarized in 
Table.
Targeting Phosphate Levels in the Body
Studies in healthy subjects have shown that circulating 
FGF23 levels are associated with dietary phosphate in-
take levels,140,141 and can be further increased by acute 
phosphate loading.142 This can be reduced, in the short- 
term, by aggressive reduction of dietary phosphate ab-
sorption141,143–146 and restriction.147 Overall, in relatively 
short- term studies, noncalcium- based phosphate bind-
ers lower FGF23 in patients with CKD/ESRD, whereas 
calcium- based binders do not.148–152 Calcium is thought 
to be a secondary stimulus for FGF23 synthesis.153,154 
However, lowering intestinal phosphate absorption with 
dietary change, phosphate binders, nicotinamide,155 
tenapanor,156–158 or combination therapy159 produces 
only modest decreases in FGF23 that do not appear 
to be sustained in the long term.150,159 Whether this is 
because of increased total intestinal phosphate absorp-
tion by active phosphate transport,160–162 high pill bur-
den, or intolerability of the medications is unknown.
Targeting Vitamin D
There is strong experimental data supporting vitamin 
D as a potential treatment for FGF23- mediated uremic 
cardiomyopathy. Calcitriol, the synthetic analogue of 
vitamin D3, blocks FGF23- induced activation of FGFR4 
and cardiomyocyte growth.114 Increases in FGF23 ex-
pression, FGFR4- induced calcineurin/NFAT signaling, 
and LVH in 5/6 nephrectomized rats are reduced by 
calcitriol.114 Vitamin D also increases αKlotho expres-
sion.163,164 Observational studies demonstrate a sur-
vival advantage of vitamin D therapy in patients with 
CKD/ESRD despite raising calcium and phosphate 
levels.165,166 However, in a randomized, placebo- 
controlled study in patients with CKD stages 4 to 5, 
paricalcitol (activated vitamin D2 analogue) treatment 
did not reduce LV mass.167 Taken together, these data 
suggest combining vitamin D receptor activation with 
FGF23/FGFR4 signaling blockade could have benefi-
cial synergistic actions on uremic cardiomyopathy.
Targeting Parathyroid Hormone
In patients on dialysis, the clinically available allosteric 
modulators (calcimimetics) of the calcium- sensing re-
ceptor, cinacalcet and etelcalcetide, are used to treat 
hyperparathyroidism and consistently lower circulating 
FGF23.168–172 In secondary analyses of the large and well- 
designed EVOLVE (Evaluation of Cinacalcet HCl Therapy 
to Lower Cardiovascular Events) trial, a >30% reduction 
in FGF23 in patients randomized to cinacalcet was asso-
ciated with a reduction in cardiovascular mortality, SCD, 
and admissions for heart failure. The findings were am-
plified in those with a >50% reduction in FGF23.87
In CKD patients not requiring dialysis, randomized- 
controlled trials of cinacalcet have reported significant 
reductions in FGF23, but also poor suppression of 
PTH as well as high rates of hypocalcemia and hyper-
phosphatemia.173,174 These actions are thought to ne-
gate many of the clinical benefits of calcimimetics and 
these agents are not licensed for use in patients with 
non- end- stage CKD. Nevertheless, cinacalcet remains 
a promising therapeutic option for the treatment of ure-
mic cardiomyopathy in ESRD.
Other Indirect Targets
Intensified dialysis treatment,175 renal transplantation,176 
reduced inflammation,147,177,178 and treatment of iron 
deficiency152,178–180 all reduce circulating FGF23 levels. 
Angiotensin- receptor antagonists,181 statins,182 peroxi-
some proliferator- activated receptor gamma  agonists,183 
and exercise184,185 all increase αKlotho expression. The 
clear indications for these treatments remain and may 
well continue to give further insights into the pathophysi-
ology of FGF23, but it is unlikely that these interventions 
will be used to directly target FGF23 and αKlotho.
DIRECTLY TARGETING FGF23
The mechanism(s) regulating FGF23 synthesis are 
poorly understood and no “phosphate- sensor” has 
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Table. Potential Therapies for Reversing or Preventing Uremic Cardiomyopathy by Targeting the Fibroblast Growth 
Factor- 23 and αKlotho Axis
Treatment Study Species CKD Status Outcome
Targeting phosphate
Dietary phosphate 
restriction
Burnett et al141 Human No renal impairment Reduction in serum FGF23
Antoniucci et al143 Human No renal impairment
Moe et al144 Human CKD Stage 3B to 4
Di Iorio et al145 Human CKD Stage 3A to 4
Sigrist et al146 Human No CKD & Stage 3A 
to 4
Rodriguez- Ortiz et al147 Rat 5/6 Nx
Calcium- sparing 
phosphate binders (eg, 
sevelamer)
Oliveira et al148 Human CKD Stage 3A to 4
Block et al149 Human CKD Stage 3B to 4
Chue et al150 Human CKD Stage 3
Rodelo- Haad et al151 Human ESRD on HD
Sprague et al152 Human ESRD on HD/PD
Nicotinamide Shahbazian et al155 Human ESRD on HD
Tenapanor Block et al157 Human ESRD on HD
Labonte et al156 Rat 5/6 Nx
Combination therapy 
with lanthanum and 
nicotinamide
Ix et al159 Human CKD Stage 3B to 4 No sustained reduction in serum FGF23
Targeting Vitamin D
Calcitriol Leifheit- Nestler et al114 Rat 5/6 Nx Reduction in LVH, cardiac FGF23 & FGFR4 
expression, and NFAT/calcineurin activation
Leifheit- Nestler et al114 Rat (NRVM) n/a In vitro reduction in FGF23- induced 
cardiomyocyte hypertrophy
Calcitriol & paricalcitol Lau et al163 Mice Partial renal ablation, 
phosphate loaded
Increase in serum αKlotho. No effect on renal/
parathyroid αKlotho expression
Paricalcitol Ritter et al164 Rat 5/6 Nx Preservation of renal αKlotho, and increase in 
parathyroid αKlotho expression in uremia
Targeting parathyroid hormone
Cinacalcet Moe et al87 Human ESRD on HD Reduction in serum FGF23, cardiovascular 
death, SCD, and heart failure
Charytan et al173 Human CKD Stage 3A to 4 Reduction in FGF23 and PTH
Chonchol et al174 Human CKD Stage 3A to 4 Reduction in FGF23 and PTH; increase in 
hypocalcemia
Other indirect targets
Intensified (daily) 
hemodialysis
Zaritsky et al175 Human ESRD on HD Reduction in FGF23 vs conventional 
hemodialysis
Renal transplantation Barros et al176 Human ESRD (⅘ on HD) Reduction in FGF23 and phosphate
Treatment of iron 
deficiency (eg, ferric 
citrate)
Block et al179,180 Human CKD Stage 3A to 5 Reduction in serum FGF32
Inhibition of inflammation 
(eg, NFᴋB inhibitor)
Rodriguez- Ortiz et al147 Rat No renal impairment Attenuation of LPS- induced FGF23 elevation
ATII receptor blockade Yoon et al181 Mice CsA- induced renal 
injury
Increase in renal αKlotho expression
Statins (eg, atorvastatin, 
pitavastatin)
Narumiya et al182 Mouse 
(IMCD3)
n/a In vitro upregulation of αKlotho mRNA 
expression
PPARγ agonist (eg, 
pioglitazone)
Yang et al183 Rat No renal impairment Increase in renal αKlotho expression
Exercise Matsubara et al184 Human No renal impairment Increase in serum/plasma αKlotho
Tan et al185
 (Continued)
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yet been found in mammals.186,187 Animal data have 
recently suggested that sodium- phosphate cotrans-
porter PiT2 found in bone might regulate phosphate- 
dependent FGF23 synthesis and that targeting PiT2 
could potentially reduce FGF23 synthesis.187 The de-
velopment of novel small molecules against PiT2 or the 
yet- to- be characterized PiT2- FGF23 pathway would 
give a proof of principle approach in animals for block-
ing FGF23 synthesis.
Indiscriminate FGF23 neutralization with mono-
clonal antibodies has been shown to worsen hyper-
phosphatemia, and increase vascular calcification 
and mortality in rat models of CKD.188,189 Use of anti- 
FGF23 monoclonal antibodies such as burosumab, 
currently approved for the treatment of x- linked hypo-
phosphatemia, causes severe side effects in patients 
with CKD by decreasing phosphaturia.190 Analogous 
to the use of calcimimetics, total blockade of FGF23 
may theoretically be of benefit in ESRD. From a clin-
ical therapeutic and drug development perspective, 
the ideal target would be the FGFR responsible for 
the adverse cardiac effects of FGF23 and not FGFR1, 
which is critical for maintaining normal phosphate 
levels. Indiscriminate blockade of FGFRs, although 
shown to be effective at preventing the development 
of,191 and reversing LVH in rodents,74 results in cardiac 
toxicity, hyperphosphatemia, and ectopic calcium 
deposition.192 Targeting cardiac FGFR4, especially 
Treatment Study Species CKD Status Outcome
Directly targeting FGF23
FGF23 neutralizing 
antibodies
Hasegawa et al189 Rat Anti- GBM nephritis Decrease in PTH; increase in vitamin D, calcium 
and phosphate
Shalhoub et al188 Rat 5/6 Nx In addition to above, increase in mortality & 
aortic calcification
FGFR antagonists
FGFR4 antibody Grabner et al75 Rat 5/6 Nx Attenuation of LVH
Rat (NRVM) n/a In vitro inhibition of FGF23- induced cardiac 
myocyte hypertrophy
Pan- FGFR antibody Faul et al74 Rat 5/6 Nx Attenuation of LVH
Rat (NRVM) n/a In vitro inhibition of FGF23- induced cardiac 
myocyte hypertrophy
Di Marco et al191 Rat 5/6 Nx Reduction in LV mass and fibrosis; 
improvement in ejection fraction
Yanochko et al192 Rat No renal impairment Cardiac toxicity, hyperphosphatemia and 
ectopic calcification
Sodium- phosphate  
co-transporter PiT2 
knockout
Bon et al187 Mice No renal impairment PiT2 regulates FGF23 synthesis; potential target 
for therapeutics
Directly targeting αKlotho
Intravenous αKlotho 
transgene
Xie et al198 Mice 5/6 Nx±heterozygous 
Klotho
Attenuation of cardiac hypertrophy and fibrosis
Recombinant αKlotho Hu et al
196 Mice Uni- nephrectomy + 
contralateral IR injury
Preservation of cardiac function, reduced 
hypertrophy and fibrosis; attenuation of renal 
fibrosis
Yang et al118 Mice 5/6 Nx Inhibition of LVH and reduction in myocardial 
reactive oxygen species production
Yu et al200 Mice No renal impairment Attenuation of angiotensin II- induced cardiac 
hypertrophy, fibrosis, and dysfunction
Suassuna et al199 Rat 5/6 Nx Reduction of uremic cardiac remodeling 
(hypertrophy and fibrosis)
Yang et al118 Rat (NRVM) n/a In vitro inhibition of uremic toxin- induced 
(indoxyl sulphate) myocyte hypertrophy
Small molecule αKlotho 
modulators
King et al201 Human 
(HEK293)
n/a In vitro elevation of αKlotho protein expression
5/6 Nx indicates 5/6 nephrectomized; anti-GBM, anti-glomerular basement membrane; ATII, angiotensin II; CKD, chronic kidney disease; CM, cardiomyocyte; 
CsA, cyclosporine A; eGFR, estimated glomerular filtration rate; ESRD, end- stage renal disease; FGF23, fibroblast growth factor- 23; FGFR, fibroblast growth 
factor receptor; HD, hemodialysis; HEK293, human embryonic kidney 293 cells; IR, ischemia- reperfusion; LPS, lipopolysaccharide; LV, left ventricle; LVH, left 
ventricular hypertrophy; n ∕a, not applicable; NFAT, nuclear factor of activated T- cells; NRVM, neonatal rat ventricular myocytes; PD, peritoneal dialysis; PPARγ, 
peroxisome proliferator- activated receptor γ; PTH, parathyroid hormone; and SCD, sudden cardiac death.
Table. Continued
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its αKlotho- independent activation of downstream 
signaling pathways, represents an exciting possibil-
ity. Indeed, FGFR4- blocking antibodies have been 
shown to inhibit FGF23- induced hypertrophy of iso-
lated rat cardiomyocytes in vitro, and attenuated LVH 
in a 5/6 nephrectomy rat model of CKD.75 Currently, 
very little is known about the specific FGFRs mediat-
ing the actions of FGF23 in nonmyocyte cardiac cells 
including fibroblasts, or whether blocking FGFR4 
prevents or reverses cardiac fibrosis.128 Several anti- 
FGF small molecule tyrosine kinase inhibitors and 
related compounds, monoclonal antibodies, and 
FGFR- analogues currently in development are mainly 
for use in oncology.193 Development of these agents 
specifically for the treatment of uremic cardiomyopa-
thy is, therefore, a real possibility.
DIRECTLY TARGETING αKLOTHO
In animal studies, administration of αKlotho protein has 
been shown to be effective in protecting against pro-
gression of CKD.194–197 Intravenous administration of a 
transgene- encoding soluble αKlotho reduces LVH in 
αKlotho- deficient mice.198 Recombinant αKlotho also 
attenuates cardiac remodeling, fibrosis,195,199 reac-
tive oxygen species production, and LVH117 induced 
by CKD in mice. In another study, αKlotho improved 
cardiac function and reduced hypertrophy and fibrosis 
in a mouse model of hypertension, although decreas-
ing FGF23 expression.200 However, it remains unclear 
whether αKlotho is cardioprotective in the absence of 
increased FGF23.
Elevated FGF23 and decreased circulating αKlotho 
are observed in both aging and in CKD,116,197,198 lead-
ing to speculation that both CKD and the age- related 
decline in this and other physiological functions are 
caused in part by increased FGF23 and decreased 
αKlotho.55 If true, this would assume soluble αKlotho 
acts as an inhibitor of αKlotho- independent actions 
of FGF23. Potential mechanisms include inhibit-
ing FGF23/FGFR4 signaling by either binding first to 
FGFR4 or via an initial interaction with FGF23 (decoy 
receptor). An alternative mechanism involves FGF23 
and FGFR4 forming a complex in the presence of 
soluble αKlotho but activating FRS2α/Ras/mitogen- 
activated protein inase rather than PLCγ/calcineurin/
NFAT signaling (Figure  1).55 Therefore, development 
of αKlotho- mimetics, through the development of 
protein–protein inhibitors, provides another potential 
therapeutic option. Trials of such agents to prevent 
progression of CKD are expected to start in the next 
couple of years.
To date, small molecule αKlotho modulators 
have been identified from a high- throughput screen 
of 150  000 compounds with those showing most 
promise being αKlotho transcription activators. 
Furthermore, extracellular signal- regulated kinase 
phosphorylation in FGFR- transfected cells increased, 
demonstrating an effect on FGF23 signaling.201 The 
recently discovered crystal structure of αKlotho:FG-
F23:FGFR1 in a 1:1:1 relationship has provided new 
insight into this dynamic interplay of factors and may 
reveal new therapeutic options.62 Although clearly at 
an early stage of exploration, the identification of new 
small molecules demonstrates the potential of drugs 
acting via αKlotho.
CONCLUSIONS
While patients with early stages of CKD are at in-
creased risk of atherosclerotic complications, 
later stages of kidney disease are associated with 
heart failure and sudden death caused by uremic 
cardiomyopathy. Significant progress has been 
made over the past 2 decades in our understand-
ing of, and ability to study the pathological basis 
of uremic cardiomyopathy using native T1 mapping. 
There are clear clinical data illustrating an associa-
tion of increased FGF23 and reduced αKlotho with 
uremic cardiomyopathy in patients with CKD, and 
in heart failure and AF in subjects without known 
CKD. However, whether FGF23 has a truly causal 
relationship in uremic cardiomyopathy remains con-
troversial. Characterization of the receptors and 
molecular pathways by which FGF23 might mediate 
LVH, cardiac fibrosis, and arrhythmias will help to 
identify therapeutic targets. Further work is required 
to identify the interplay between FGF23, cardiomyo-
cytes and fibroblasts, and the effects of these inter-
actions on the subsequent cardiac remodeling to 
reveal the molecular and cellular targets of FGF23 
and αKlotho. Improved understanding is likely to 
enable the development of novel therapeutic inter-
ventions capable of effectively reducing the excess 
cardiovascular risk associated with CKD/ESRD, and 
perhaps even the risk of AF and heart failure in pa-
tients without CKD.
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